<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334187</url>
  </required_header>
  <id_info>
    <org_study_id>19-01435</org_study_id>
    <nct_id>NCT04334187</nct_id>
  </id_info>
  <brief_title>NYCHA Mindfulness-based Smoking Cessation Intervention</brief_title>
  <official_title>Feasibility and Accessibility of a Mindfulness-based Smoking Cessation Intervention for NYCHA Residents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess feasibility, accessibility and impact of a mindfulness-based smoking&#xD;
      cessation group intervention for New York City Housing Authority (NYCHA) residents. Residents&#xD;
      who smoke to receive an 8-week intervention. Participants will also be offered 4 weeks of&#xD;
      nicotine replacement therapy (NRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this research is to examine the feasibility, accessibility and&#xD;
      impact of a mindfulness-based smoking cessation program for NYCHA residents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who perceive the Mindfulness based addiction treatment as useful at time of Enrollment</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants will report their perceived usefulness and effectiveness of the intervention using self reported surveys at enrollment (baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who perceive the Mindfulness based addiction treatment as useful after last MBAT session.</measure>
    <time_frame>2 months</time_frame>
    <description>Number of participants will report their perceived usefulness and effectiveness of the intervention using self reported surveys after their last MBAT session (2 months after enrollment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who perceive the Mindfulness based addiction treatment as useful post treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Participants will report their perceived usefulness and effectiveness of the intervention using self reported surveys one month after completing treatment (3 months post-enrollment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who perceive the Mindfulness based addiction treatment as effective</measure>
    <time_frame>3 months</time_frame>
    <description>Participants who self-report 7-day abstinence in the final follow up survey (3 months) will provide a biochemically validated saliva sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who adhered to the Mindfulness based addiction treatment</measure>
    <time_frame>3 months</time_frame>
    <description>This will be reported in the number of sessions attended and completed mindfulness exercises in between the sessions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who self reported abstinence</measure>
    <time_frame>2 months</time_frame>
    <description>This will be self reported at the end of the treatment (2 months)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tobacco Use</condition>
  <arm_group>
    <arm_group_label>Smoke Cessation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-based smoking cessation sessions will follow the mindfulness based addiction treatment (MBAT) intervention for smoking cessation. Sessions are in group format for two hours, weekly. Two groups of sessions with about 10 participants per group will be organized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness Based addition treatment</intervention_name>
    <description>The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.</description>
    <arm_group_label>Smoke Cessation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Current smoker (&gt;= 5 cigarettes per day). Dual tobacco users are eligible as long as&#xD;
             their primary tobacco product is cigarettes.&#xD;
&#xD;
          -  Ready to quit smoking cigarettes within 30 days&#xD;
&#xD;
          -  Able to attend the 8 weekly MBAT sessions at the scheduled days/times&#xD;
&#xD;
          -  NYCHA resident&#xD;
&#xD;
          -  English language&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Patient Health Questionnaire-2 (PHQ-2) score indicating current risk for depression&#xD;
&#xD;
          -  Self-reported diagnosis of schizophrenia, bipolar disorder, schizotypal disorder or&#xD;
             other psychotic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin Rogers</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Wysota</last_name>
    <phone>646-501-3592</phone>
    <email>Christina.Wysota@nyulangone.org</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data. Upon reasonable request. Requests should be directed to Erin.rogers@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

